Asia Pacific Alopecia Treatment Market Size to Exceed USD 4,477.8 Mn by 2032

The Asia Pacific Alopecia Treatment Market, estimated at USD 2,825.3 Mn in 2025, is expected to exhibit a CAGR of 6.8% and reach USD 4,477.8 Mn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

The Strategies by key players are focused on clinical trails for developing new drugs is expected to drive the Asia Pacific alopecia treatment market growth over the forecast period. For instance, on March 28, 2023, Kintor Pharmaceutical Limited, a China-based clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has completed the enrollment of 740 subjects recently for the Phase III clinical trial of its in-house developed first-in-class drug candidate KX-826 (pyrilutamide) in China for the treatment of male androgenetic alopecia (AGA) adults.

Asia Pacific Alopecia Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others faced problems regarding transportation of drugs from one place to another.

COVID-19 had negative impact on the Asia Pacific alopecia treatment market. For instance, on September 12, 2022, QR678 is a proprietary, first in class hair fall & hair regrowth therapy developed by derma clinic explained the Covid-19 pandemic has caused a substantial increase in the frequency of incidences of transitory reversible hair loss in post-Covid patients as a result of psychological and physical stress. After the patient has recovered from Covid, hair loss typically starts two to three months later. After about 55 days following recovery, there is typically a notable loss of hair. There are several restrictions to the many hair-regrowth treatments available on the market, and they cannot restore hair past a certain stage. When used in conjunction, non-surgical hair regrowth methods include over-the-counter topical minoxidil, prescription oral finasteride, platelet-rich plasma (PRP) injections, and light and laser therapy might help prevent hair loss. However, these methods can occasionally have unfavorable side effects.

Asia Pacific Alopecia Treatment Market: Key Developments

Increasing launch of new range of products that can improve the efficacy of alopecia treatments is expected to drive the market growth.

For instance, On June 20, 2023, Stylecraze Private Limited, an India-based company developed the five Chinese Herbs that may help in treating hair loss. From which one is Reishi mushrooms are often used in hair tonics. It is also called lingzhi. It has antioxidant, antiviral, antimicrobial, anti-inflammatory, and antibacterial properties. It has anti-aging and anti-pigmentation properties that help keep hair healthy. It can also protect hair from light damage. A study on mice shows that this reishi mushroom has hair-raising properties and can be used against hair loss.

Browse 25 Market Data Tables and 29 Figures spread through 160 Pages and in-depth TOC on Asia Pacific Alopecia Treatment Market, , By Treatment Type (Topical Drugs (Creams, Oils, Gels, Shampoo, Lotions, Foam Oral Drugs, Injectables ( Platelet Rich Plasma, Steroid Injections, Injectable Filler), Hair Transplant Services,  Low-Level Laser Therapy),  By Disease Indication (Alopecia Areata,  Alopecia Totalis,  Alopecia Universalis), By End User (Hospitals, Dermatologic and Trichology Clinics, Home care settings, Aesthetic Clinics), and By Country (China, Japan, Australia, New Zealand, Malaysia, India, Singapore, Vietnam, Philippines, Rest Of APAC)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/asia-pacific-alopecia-treatment-market-3958

Key Takeaways of the Asia Pacific Alopecia Treatment Market:

• Asia Pacific Alopecia Treatment Market is expected to exhibit a CAGR of 6.8% during the forecast period. For instance, March 7, 2023 Indimedo pharmacy explained the causes of alopecia as enetics: Studies have shown that people with a family history of alopecia areata are more likely to develop the condition. Autoimmune disorders: Alopecia areata is often associated with other autoimmune disorders, such as thyroid disease or vitiligo. Stress: Emotional or physical stress can trigger the onset or exacerbation of alopecia areata. Infections: Some infections, such as viral or bacterial infections, may trigger the immune system and lead to alopecia areata. Environmental factors: Exposure to certain environmental factors, such as chemicals or pollutants, may increase the risk of developing alopecia areata. Hormonal changes: Changes in hormones may trigger alopecia areata, particularly in women who have just given birth or are going through menopause.
• Among treatment type, oral drugs segment is expected to dominate the Asia Pacific Alopecia Treatment Market over the forecast period, owing to launch of new drugs. For instance, on November 9, 2022 Excel Pharma explained effective Homeopathic medicines for human and veterinary problems. Effective Homeopathic medicine for alopecia areata, like E- Hair Plus Drops (AKG -07) and E-Jaboran Lotion (AKG-50)
• Among region, China is expected to be the dominant region in the Asia Pacific Alopecia Treatment Market, owing to the increasing launches of newer research in the country. For instance, on July 7, 2021 Chinese Journal of Dermatology explained small-molecule targeted drugs and biological agents have advantages of more rapid and marked efficacy, however, some patients may experience adverse reactions such as infections during treatment or relapses after drug withdrawal.
• Major players operating in the Asia Pacific alopecia treatment market include Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Johnson & Johnson, Inc., Pfizer, Inc., Dr. Reddy’s Laboratories Ltd, Cipla Ltd, Cellmid Ltd., The Himalaya Drug Company, Taisho Pharmaceutical Holdings Co. Ltd., and Shiseido Co., Ltd.